The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States
Abstract
Objective—: Elevated lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease and aortic stenosis. We aimed to define the prevalence and patient thresholds of elevated Lp(a) levels in the United States. Approach and Results—: We analyzed Lp(a) levels in 532 359 subjects from 2 data sets: (1) in 531 144 subjects from a referral laboratory and (2) in 915 patients from a tertiary referral center. Lp(a) mass levels were measured by immunoturbidometric assays in both centers and expressed as mg/dL. At the referral laboratory, the median age (interquartile range) of the subjects was 57.0 (46–67) years, and 51.9% were female. Lp(a) levels were skewed rightward as expected. The mean±SD levels were 34.0±40.0 mg/dL, and median (interquartile range) levels were 17 (7–47) mg/dL, with range 0 to 907 mg/dL. Lp(a) levels at 75%, 80%, 90%, 95%, 99%, and 99.9% percentiles were >47, >60, >90, >116, >180, and >245 mg/dL, respectively. At the referral laboratory, Lp(a) levels >30 and >50 mg/dL were present in 35.0% and 24.0% of subjects, respectively, and at the tertiary referral center, 39.5% and 29.2%, respectively. Females had higher mean (SD) (37.0 [42.7] versus 30.7 [36.7]; P <0.0001) and median (interquartile range) (19 [8–53] versus 15 [7–42]; P <0.0001) Lp(a) than males. Conclusions—: This is the largest database to assess the distribution of Lp(a) and is derived from patients as opposed to general populations. Lp(a) levels >30 and >50 mg/dL were fairly common, particularly in a tertiary care setting. These data may inform consensus documents, guidelines, and therapeutic cutoffs for Lp(a)-mediated cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“In fact, in the several Copenhagen studies published to date in general populations, from which the EAS recommendations were actually derived, the data most strongly support a risk starting at >≈20 mg/dL or the 67th percentile.(2,19,20) Consistent with these data, in the Emerging Risk Factor Collaboration, Lp(a) level…”
BackgroundElevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
Self-citationExtreme lipoprotein(a) levels and improved cardiovascular risk prediction
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.023 · Cited by 284
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Burgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689
“96)andthusmayrepresent an inherited lipoproteindisorder that is associatedwitha similar lifetimeriskofCHDasheterozygous familialhypercholesterolemiabutwithaprevalencethatmaybe2-foldhigher thanthat ofheterozygous familial hypercholesterolemia.(32,33)Therefore, screeningfor individualswithextremelyelevatedLp(a)concentra…”
BackgroundWilleit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Self-citationLipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau, F., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 363
Metadata
- Authors
- Varvel, S., McConnell, J. P., & Tsimikas, S.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-11
- Volume
- 36
- Issue
- 11
- Pages
- 2239-2245
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2521514852
- Cited by
- 218
- References
- 7
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. https://app.cochat.ai/papers/10.1161/atvbaha.116.308011
- The paper
- Varvel, S., McConnell, J. P., & Tsimikas, S. (2016). Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.116.308011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.